Go Deep
Titan Biotech Limited
Titan Biotech Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 21,520 | 257.8 | 9.09 | 0.03 | 399.55 |
| Sep 2026 | 21,542 | 255.6 | 9.07 | 0.03 | 398.70 |
| Sep 2026 | 21,844 | 249.3 | 8.79 | 0.03 | 386.40 |
| Sep 2026 | 21,844 | 249.3 | 8.79 | 0.03 | 386.40 |
| Sep 2026 | 21,844 | 249.3 | 8.79 | 0.03 | 386.40 |
| Sep 2026 | 21,708 | 252.8 | 8.92 | 0.03 | 391.90 |
| Oct 2026 | 20,810 | 249.4 | 8.91 | 0.03 | 391.50 |
| Oct 2026 | 20,136 | 47.9 | 8.94 | 0.03 | 392.60 |
Titan Biotech Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 591,666,000.0 | 488,335,000.0 | 565,057,000.0 | 543,547,000.0 |
| Net Profit | 108,568,000.0 | 67,291,000.0 | 85,286,000.0 | 77,647,000.0 |
| EPS | 2.6 | 1.6 | 2.1 | 1.9 |
Titan Biotech Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 2,061,903,000.0 | 1,564,508,000.0 | 1,640,721,000.0 | 1,439,993,000.0 | — |
| Net Profit | 298,852,000.0 | 215,316,000.0 | 248,530,000.0 | 248,442,000.0 | — |
| EPS | 7.2 | 5.2 | 6.0 | 6.0 | — |
Titan Biotech Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 2,138,848,000.0 | 1,747,075,000.0 | 1,570,253,000.0 | 1,345,151,000.0 | — |
| Total Liabilities | 323,373,000.0 | 213,043,000.0 | 235,741,000.0 | 246,042,000.0 | — |
| Total Equity | 1,815,475,000.0 | 1,534,032,000.0 | 1,334,512,000.0 | 1,099,109,000.0 | — |
Owes vs Owns
Titan Biotech Limited owed ₹0.15 for every ₹1 it owned in Mar 2026, down from ₹0.18 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.15× | 0.12× | 0.15× | 0.18× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Titan Biotech Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 0.7%Receivables 10.7%Inventory 26.1%Fixed assets (tangible) 29.6%Long-term investments 12.7%Other assets 20.3%
How it's funded — Mar 2026
Short-term debt 1.6%Payables 4.0%Other liabilities 9.4%Shareholders' equity 84.9%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 1.5 | 5.1 | 2.8 | 4.9 |
| Receivables | 22.8 | 18.8 | 18.7 | 21.0 |
| Inventory | 55.8 | 50.8 | 45.9 | 36.6 |
| Fixed assets (tangible) | 63.3 | 58.8 | 54.5 | 49.1 |
| Intangible assets | 0.1 | 0.1 | 0.1 | 0.1 |
| Long-term investments | 27.1 | 36.7 | 13.8 | 10.6 |
| Other assets | 43.4 | 4.3 | 21.3 | 12.3 |
| Liabilities & equity | ||||
| Short-term debt | 3.3 | 1.9 | 6.7 | 6.7 |
| Long-term debt | 0.3 | 0.2 | 0.5 | 0.3 |
| Payables | 8.5 | 7.7 | 3.4 | 5.5 |
| Other liabilities | 20.1 | 11.5 | 13.0 | 12.1 |
| Shareholders' equity | 181.5 | 153.4 | 133.5 | 109.9 |
| Net tangible assets | 181.5 | 153.3 | 133.4 | 109.8 |
Titan Biotech Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 304,208,000.0 | 201,233,000.0 | 211,463,000.0 | 211,784,000.0 | — |
| Investing Activities | -325,459,000.0 | -98,533,000.0 | -203,037,000.0 | -207,252,000.0 | — |
| Financing Activities | -15,251,000.0 | -79,822,000.0 | -28,662,000.0 | -24,034,000.0 | — |